Boston Scientific Co. (NYSE:BSX) Shares Bought by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 9.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,108 shares of the medical equipment provider’s stock after acquiring an additional 1,263 shares during the period. Fidelis Capital Partners LLC’s holdings in Boston Scientific were worth $1,115,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. CVA Family Office LLC lifted its position in Boston Scientific by 7.4% in the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock valued at $147,000 after purchasing an additional 131 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Boston Scientific by 0.6% in the 2nd quarter. International Assets Investment Management LLC now owns 22,596 shares of the medical equipment provider’s stock valued at $1,740,000 after buying an additional 139 shares during the period. ST Germain D J Co. Inc. boosted its stake in shares of Boston Scientific by 8.0% in the second quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock valued at $148,000 after buying an additional 143 shares in the last quarter. Pinnacle Associates Ltd. raised its position in Boston Scientific by 2.0% in the first quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after acquiring an additional 148 shares in the last quarter. Finally, Transcend Capital Advisors LLC lifted its holdings in Boston Scientific by 2.2% in the second quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 148 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BSX shares. TD Cowen increased their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. increased their target price on shares of Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a research note on Thursday, July 25th. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, September 13th. Finally, Needham & Company LLC lifted their price objective on Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.65.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 20,949 shares of company stock valued at $1,627,877 over the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $83.92 on Monday. The stock has a market capitalization of $123.12 billion, a P/E ratio of 70.52, a P/E/G ratio of 2.75 and a beta of 0.79. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The firm’s 50-day moving average is $78.72 and its two-hundred day moving average is $74.73.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.53 earnings per share. Equities analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.